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Abstract 
 
Mef2 is a conserved and significant transcription factor in the control of muscle gene expression.  In cell 
culture Mef2 synergises with MyoD-family members in the activation of gene expression and in the 
conversion of fibroblasts into myoblasts. Amongst its in vivo roles, Mef2 is required for both Drosophila 
muscle development and mammalian muscle regeneration.  Mef2 has functions in other cell-types too, but 
this review focuses on skeletal muscle and surveys key findings on Mef2 from its discovery, shortly after that 
of MyoD, up to the present day. In particular, in vivo functions, underpinning mechanisms and areas of 
uncertainty are highlighted. We describe how Mef2 sits at a nexus in the gene expression network that 
controls the muscle differentiation program, and how Mef2 activity must be regulated in time and space to 
orchestrate specific outputs within the different aspects of muscle development. A theme that emerges is 
that there is much to be learnt about the different Mef2 proteins (from different paralogous genes, spliced 
transcripts and species) and how the activity of these proteins is controlled. 
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1.  Discovery of the conserved Mef2 family 
 
We write on the thirtieth anniversary of the publication of the paper describing the discovery of MyoD 
and its ability to transform a fibroblast into a myoblast ([1] Lassar, this special issue).  It is difficult to 
overstate the impact of this discovery both to the field of muscle differentiation and also beyond, to cell 
differentiation programs in general and to cellular reprogramming.   In mammals, MyoD was quickly identified 
as one of four structurally and functionally related transcription factors, the Myogenic Regulatory Factors 
(MRFs)[2].  They bind to specific DNA sequences found in the cis-regulatory modules (CRMs) that control 
the expression of many muscle genes, and together the MRFs have a critical role in muscle differentiation 
during animal development [3].  However, there is more to making muscle than the MRFs.  For example, 
other DNA sequences in CRMs together with their cognate transcription factors are required for muscle gene 
expression.  Indeed, MRFs can induce gene expression through DNA sequences that do not contain their 
binding site [4, 5].  Mef2 quickly emerged as another significant player in the transcription of muscle genes.   
Mef2 was first identified using mammalian cultured cells [6].  It was described as a protein activity 
that bound to a DNA sequence, distinct from the MRF-binding site, found in a CRM of the muscle creatine 
kinase (MCK) gene that is responsible for the expression of MCK during muscle cell differentiation.  This 
Mef2-binding DNA sequence was subsequently found to be in the CRMs of nearly every known muscle-
specific gene [5, 7].  Molecular cloning of Mef2 [8, 9] revealed that Mef2 is a member of the evolutionarily 
ancient MADS family of transcription factors [10, 11].  This family also contains SRF, which itself has a role 
in the regulation of muscle gene expression [12] and references cited therein; [13].   
Mef2 is highly conserved (Fig. 1).  There are single Mef2 genes in Drosophila, C. elegans and sea 
urchins, for example [7].  In contrast in the vertebrate genome, as with the MyoD family of MRFs, there are 
four closely-related Mef2 genes: Mef2a, -b, -c and -d [7].  Different transcripts are generated from each gene 
by alternative splicing [7, 9] (see 5.1 for functional significance). The encoded proteins bind DNA with the 
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consensus sequence CTA(A/T)4TAG and can form both homo- and hetero-dimers [8].  It is unknown whether 
different Mef2 isoforms bind to variants of the Mef2 consensus sequence [14].  Key functional domains 
include the N-terminal MADS box and the adjacent Mef2 domain, that together are necessary and sufficient 
for DNA-binding and dimerisation, and these regions show extensive sequence similarity across all the Mef2 
proteins from different species [7]. Point mutations in the conserved MADS box of Drosophila Mef2 result in 
lethality [15].  The C-terminal region is required for transcriptional activation [16], but the sequence has 
diverged considerably in different Mef2 proteins.  Mef2 protein bends DNA on high affinity binding [17], and 
while the MADS box confers DNA-binding specificity [8], the Mef2 domain modulates the DNA-binding 
affinity [16]. Both crystal and solution structures for a homodimerised highly conserved MADS/Mef2 domain 
of MEF2A bound to DNA have been determined [18-20]. Many aspects of the Mef2 structure/function 
relationship remain to be analysed. 
 
2. Mef2 gene expression  
 
An initial step in the investigation of the possible role of Mef2 in muscle differentiation was to 
determine its pattern of expression during embryonic development.  Moreover, the expression pattern of 
individual genes, and indeed isoforms of each gene, continues to aid the interpretation of phenotypes and 
yield insights into the role of individual gene products. We will focus on Mef2 in skeletal muscle although, 
and in contrast to the skeletal muscle-specific MRFs, Mef2s are expressed and function in cardiac and 
smooth muscle, endothelium, brain neurons and many other tissues [21].   
Invertebrates have a single Mef2 gene. In Drosophila, Mef2 is initially expressed throughout the 
mesoderm at gastrulation and subsequently almost exclusively in muscle.  Both progenitors and 
differentiated cells of the somatic muscle (the equivalent of vertebrate skeletal muscle), heart and visceral 
muscle express Mef2 [22].  The situation is more complex in vertebrate species with their separate Mef2a, -
b, -c and -d genes. Mouse was the first species in which their expression patterns were described during 
development. 
Murine Mef2 genes are expressed at significant levels in a wide variety of tissues, but several show 
highest expression in muscle. Mef2c mRNA was first detected in the developing heart and shortly after in 
somitic muscle, and remained abundant in developing skeletal muscle at e14.5, being particularly 
concentrated at points of muscle attachment [23, 24].   Mef2d showed a similar although weaker pattern in 
somitic muscle [23].  Mef2a is also highly expressed in somites containing differentiated muscle fibres 
[23].  Mef2b has the most divergent structure, the least obvious muscle-related expression and the least 
evidence for involvement in muscle development. The expression pattern of the Mef2 genes during limb and 
head myogenesis is, to our knowledge, poorly described.   
A striking feature of chick Mef2 expression is that it is biphasic.  Mef2b and Mef2c show broad 
transient expression in nascent neck somites, prior to MRF expression [25].  In contrast later, in nascent 
trunk somites, Mef2c mRNA accumulates strongly prior to other Mef2 mRNAs in regions where both Myf5 
and MyoD have become detectable [25].   Mef2d and Mef2a mRNAs are detected in each somite, a few 
hours after Mef2c [25, 26].  At slightly later stages, when terminally differentiated fibres are present in 
significant numbers in somites, the location of Mef2c and Mef2d mRNAs appear distinct, with Mef2c mRNA 
located at the dermomyotomal lips where new myogenesis is on-going and Mef2d mRNA located centrally 
within the myotome where more mature fibres are located [25].  Thus, Mef2c and Mef2d display a spatial and 
Taylor and Hughes Mef2 Pg  4 
temporal succession.   This description reveals potentially interesting relationships both between the different 
Mef2 genes and to the MRFs, but the functional significance of this expression is at present unknown. 
Zebrafish have six Mef2 genes, both mef2a and mef2c have two versions, and several are 
expressed during skeletal myogenesis [27].  Zebrafish mef2d is the first Mef2 gene detectably expressed, 
closely following the initiation of MRF expression in several distinct muscle precursor cell populations [28, 
29].   Mef2ca mRNA accumulates later, in parallel with myosin expression, in several distinct myocyte 
populations as each begins to elongate and assemble myofibrils [29].   mef2aa and mef2cb are expressed in 
skeletal muscle after mef2d [30-36], but are not fully described. Expression patterns 
of mef2b and mef2ab have not been described, although neither was detected in somitic muscle at 2 days of 
age [35]. Mef2 immunoreactivity is particularly abundant in striated muscle [27, 29, 37-40].  Overall, it is clear 
that at least four Mef2 genes are sequentially expressed at high level during terminal differentiation of 
skeletal muscle in teleost fish. 
Taken together, these studies show prominent and regulated expression of Mef2 genes during 
muscle development in a range of species.  However, a lack of consensus across species in the order and 
location of expression of the four vertebrate Mef2 genes suggests that either underlying common patterns 
have been missed, or that gene usage has changed during evolution.  Future studies at higher spatial and 
temporal resolution may resolve precisely when and where each Mef2 protein is available to function. 
 
3. What does Mef2 do in muscle?  
 
The prominent position of Mef2 in the field of muscle differentiation derives both from two early 
findings in mammalian cell culture and during development of Drosophila melanogaster, and from later work 
in a variety of model systems. 
 
3.1 Mammalian cell culture 
 
The first of these influential early studies uncovered a functional interaction between Mef2 proteins 
and MRFs [41].  The characteristic and striking property of the MRFs is that they can convert fibroblasts into 
myoblasts.  This ability is greatly enhanced when MRFs are co-transfected with Mef2 [41]. Specifically, 
MyoD synergised with each of Mef2a, Mef2c and Mef2d, and Myogenin with Mef2c.  Members of these two 
families of transcription factors also synergistically activated reporter gene expression [41].  This functional 
cooperation required direct physical interaction between the DNA-binding domains of both Mef2 and the 
MRF.  Strikingly, it could occur through multiple copies of the binding sites for either Mef2 or MRF in the 
reporter construct. The study indicated that the two proteins could activate gene expression in two ways: (1) 
through binding to separate DNA sites; or (2) at a single site through a proposed Mef2/MRF physical 
interaction.  Although muscle gene CRMs often contain nearby sites for the two factors [7, 42-45], the latter 
finding means that either factor could also activate transcription through the other’s binding site. This offers 
an explanation for how MRFs can induce muscle gene expression through DNA sequences that do not 
contain an MRF-binding site [4, 5].  
Mutational analyses of MRFs had revealed that an alanine and a threonine in their DNA-binding 
domain are required for muscle gene activation [46, 47].  However, these amino acids are not required for 
DNA-binding, and so it was proposed that they are necessary for an interaction with a co-regulatory factor 
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required for muscle gene activation.  Strikingly, the synergistic interaction between Mef2 and MRFs in both 
myogenic conversion of fibroblasts and expression of reporter genes requires these two specific amino 
acids, suggesting that Mef2 factors are the proposed co-regulators for the MRFs [41]. However, definitive in 
vivo evidence for such direct interactions is still lacking. 
This research was complemented by a loss-of-function study that used a ‘dominant negative’ Mef2 
construct to show that Mef2 family function is required by MRFs for the myogenic conversion of fibroblasts 
[48].  The same construct also inhibits formation of myotubes from C2C12 myoblasts.  More recently, an 
alternative approach of knocking down Mef2a expression using a Mef2a-specific shRNA also impaired 
C2C12 myotube formation [49].  Together these cell culture studies point to an intriguing function of Mef2, 
but it was critical to probe the role of Mef2 in the much more complex in vivo situation, i.e. during the muscle 
differentiation program of gene expression in animal development.  However, such analyses in vertebrates 
have been complicated by the aforementioned four closely-related Mef2 genes, with their overlapping 
expression patterns in multiple tissues.  
 
3.2 Mef2 function in Drosophila 
 
The second influential early finding came from the analysis of Mef2 function in Drosophila. Its single 
Mef2 gene encodes a highly conserved MADS/Mef2 domain and is also alternatively spliced, in common 
with other species [50](Fig. 1).  With the efficient genetics available, Drosophila was used to show that Mef2 
is required for muscle development during embryogenesis.  Mef2 mutant embryos lack differentiated somatic 
muscle [22, 51, 52].  Although somatic muscle progenitor cells are produced in a substantially unaffected 
pattern, they fail to fuse and differentiate further.  The dominant conclusion from this period of Mef2 research 
was that it affects myogenesis relatively late, during the overt differentiation phase.  We will return to this 
point in Section 4.1.  Although the focus of this review is on skeletal muscle, it is of interest that Mef2 is also 
required for proper differentiation of both the heart and visceral muscle, and again early steps in their 
development appear substantially unaffected.  Thus, Drosophila Mef2 is required for the differentiation of all 
the major muscle-types.  As many muscle genes are expressed in multiple muscle-types, it is noteworthy 
that Mef2 might regulate some of the same genes in each, something that the MRFs cannot do. 
There are two phases of myogenesis in Drosophila and Mef2 is required for each.  The first phase 
produces the larval musculature during embryogenesis, and the second produces the adult musculature 
during metamorphosis.  Drosophila adult somatic muscles are physiologically and functionally diverse and, 
unlike the larva, some contain multiple fibres, characteristics that are in common with vertebrate skeletal 
muscles [53-56].  The largest muscles include the dorso-longitudinal indirect flight muscles (DLMs).  The 
Mef2 mutants used to establish a function in the first phase of myogenesis are embryonic lethal, but other 
Mef2 hypomorphic mutants were found to have a reduced number of abnormally patterned DLMs [15, 57, 
58].  More recently, temporally and spatially controlled expression of RNAi to knock-down Mef2 function only 
in adult myogenesis has shown that Mef2 is required for a diverse range of adult muscle types, including the 
DLMs and also the structurally distinct jump and leg muscles [59, 60]. DLMs are formed by a type of 
regeneration in a remodelling process during metamorphosis.  Early in pupation, template larval muscles 
fuse with muscle progenitor cells that are maintained in an undifferentiated state in the larva. In early pupae 
in the RNAi Mef2 loss-of-function condition, unfused myoblasts are found around the muscle templates, 
remodelling is inhibited, and at the end of pupation DLMs are completely absent.  Of note, Mef2 functions at 
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several distinct times in this muscle differentiation program (see 4.1). Temperature sensitive control of the 
Mef2 RNAi expression showed that Mef2 is required first for normal remodelling and then subsequently in 
promoting muscle maintenance [59].  Remodelling and maintenance are important aspects of tissue biology, 
and the functions for Mef2 in these processes may have implications for muscle repair.   
 
3.3 Function of zebrafish Mef2 
 
Mef2 gene function in zebrafish skeletal muscle has been examined by a combination of loss- and 
gain-of-function analyses.  With the exception of mef2ca mutants, which show delayed cardiomyogenesis 
and reduced somitic myotome volume and muscle fibre size, strong skeletal muscle phenotypes of single 
Mef2 gene mutants or antisense morpholino knockdowns have not been reported [29, 33-
35].  Mef2ca;mef2cb double mutants have a severe lack of cardiomyogenesis, but no additional defect in 
skeletal myogenesis was described [34]. Nevertheless, knockdown of several Mef2 proteins with either a 
single broad-spectrum anti-Mef2 morpholino or a combination of mef2ca loss-of-function mutation with a 
specific Mef2d morpholino yielded a failure of proper sarcomere assembly and reduction in mRNA levels for 
a variety of sarcomeric proteins [29]. In contrast, mef2cb single mutants failed to show the cardiac-specific 
phenotype observed by two independent labs in Mef2cb morphants [33, 34].  In our view, therefore, results 
from morpholino studies should be treated with caution until either replicated by clean genetic analyses or a 
molecular mechanism is demonstrated explaining compensatory changes that rescue mutants [61]. Loss-of-
function mutations in the other Mef2 genes are yet to be described.  Taken together, these functional 
analyses suggest that a combination of Mef2 genes contribute to the overall Mef2 activity in skeletal muscle 
that is needed for proper myogenesis downstream of the MRF proteins and muscle growth, at least in part 
through effects on sarcomere assembly. 
Although Mef2s normally act downstream of MRFs in skeletal myogenesis, once expressed Mef2s 
may also play a role in promoting MRF activity (see section 4.4).  Over-expression of Mef2cb in zebrafish 
embryos leads to myod mRNA accumulation and slow myosin heavy chain expression in significant regions 
of cranial mesoderm [34, 36]. Over-expression of Mef2ca, on the other hand, does not induce these muscle 
genes, but instead appeared to dorsalize embryos, perhaps through up-regulation of BMP inhibitors such as 
chordin within the somite [36].  These data and others on the differential effects of splice variants (see 5.1) 
indicate that much remains to be learned about Mef2 function in specific times, places and types of skeletal 
myogenesis. 
 
3.4 Function of mouse Mef2 
 
Loss-of-function alleles of Mef2a, Mef2c and Mef2d have been generated by deleting the second 
coding exon [14].  There is no obvious skeletal muscle phenotype in Mef2a and Mef2d mutants.   Mutants in 
Mef2c are early embryonic lethal shortly after somite formation, presumed due to cardiovascular defects.  
Nevertheless, a defect in the earliest stages of skeletal muscle development was suggested based on loss of 
expression of a reporter transgene in the somites [62].  The effect of Mef2c has been further explored 
through conditional knock out studies.  Using a skeletal muscle specific Cre-recombinase line active from 
stage E8.5 to delete a floxed Mef2c allele, it was found that the mice die at post-natal day 1 with severely 
disorganized and fragmented skeletal muscle [63]. However, skeletal muscle differentiated and formed 
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normal myofibers during embryogenesis, but such myofibers subsequently and rapidly deteriorated with 
disorganized sarcomeres.  It was concluded that Mef2c plays a key role in the maintenance of sarcomere 
integrity [63]. 
It should be noted that in another study using a very similar approach to the conditional loss-of-
function of Mef2c in skeletal muscle, the mice were viable and did not show perinatal lethality [64].  
Moreover, both sarcomere organisation and muscle ultrastructure were grossly normal, although there was a 
reduction in slow muscle fibres (see 3.7), and a function for muscle Mef2c was also identified in normal 
growth and glucose metabolism.  The mice in this study had a slightly different Cre line in a different genetic 
background, and a fuller discussion of the possible impact of these two aspects is presented in [64].  Such 
differing findings suggest the role of Mef2c may be more complex than hitherto understood, perhaps due to 
differing functions in several muscle-related cell types.   
 
3.5 Potential functions in muscle-related tissues 
 
Chick Mef2c is expressed early and broadly in mesoderm, suggesting it may affect development of 
various tissues [25]. Over-expression of zebrafish Mef2cs in heterologous systems may influence osteo- or 
chondrogenesis through Sox9/BMP [65].   After initial myogenesis, zebrafish mef2ca mRNA becomes 
localised to fibre ends, whereas Xenopus Mef2c has been suggested to function in early tendon cells [29, 
66]. Similarly, early expression of Mef2d in Xenopus may promote dermomyotome formation in addition to 
specific aspects of myogenesis [67, 68]. These observations caution that potential roles of Mef2 in muscle-
related tissues could impact on muscle phenotypes observed and suggest that more research is required to 
define the cell autonomous roles of the Mef2 genes in muscle development in vivo.  
 
3.6 Mef2 in muscle regeneration 
 
Muscle regeneration in response to injury is a type of myogenesis related to, but distinct from, that 
occurring during development.  It is dependent on satellite cells, a population of stem cells found underneath 
the basal lamina of muscle fibres (Zammit, this special issue). These cells generate myoblasts in post-natal 
skeletal muscle for both growth and for regeneration following injury, and become depleted in degenerative 
muscle diseases.  The potential involvement of Mef2 factors in muscle regeneration has been investigated. 
Loss of Mef2a slows regeneration ([49], but see [69] for discussion of cell autonomy).  Conditional deletion of 
the individual Mef2a, -c or -d genes in mouse satellite cells in vivo has no effect, but the combined 
conditional deletion of all three genes results in a block to regeneration [69].  Analysis suggests this is due to 
the Mef2 genes affecting the myoblast differentiation aspect of the regeneration process.  This is the clearest 
demonstration to date of a function for Mef2 genes in mammalian muscle differentiation in vivo and echoes 
the role of Mef2 in the remodelling of Drosophila DLMs, a process with parallels to mammalian muscle 
growth and repair (see 3.2).  As redundant roles for three Mef2 genes were revealed in murine muscle 
regeneration, it is possible that there might be a similar situation in embryonic muscle development that has 
prevented phenotypes being observed in single Mef2 gene knockouts.   
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3.7 Mef2 and muscle fibre character  
 
Mef2 proteins have been implicated in the control of various aspects of muscle fibre character, either 
through developmental roles or by direct action in the adult fibre.  Muscle fibres differ in size, contractile 
speed and metabolic properties based on the electrical activity imposed by the nerve that confers specific 
physiological characteristics to force production (reviewed in [70]).  Such characteristics are frequently 
summarized by the term ‘fibre type’. Evidence exists that Mef2 regulates both muscle fibre type and size, but 
how the two effects are discriminated remains unclear.  On some genetic backgrounds, muscle-specific 
deletion of mouse Mef2c can reduce muscle growth and sarcomere assembly [63].  Similarly, both 
embryonic zebrafish and mouse postnatal muscle growth was reduced after Mef2c knockdown and, in 
mouse, remaining muscle had altered contractile and metabolic properties [35, 64]. Conversely, in adult 
zebrafish, exercise increased muscle fibre size, mef2aa and mef2d mRNAs, but decreased mef2ca mRNA 
[71]. Thus, the relationship between Mef2 and fibre character appears complex. 
Analysis of adult mice in which floxed Mef2c or Mef2d alleles were recombined in skeletal muscle by 
Cre driven from early-muscle transgenes has implicated Mef2 activity in the regulation of murine muscle fibre 
type [64, 72].  In vitro analyses show Mef2 can cooperate with a variety of factors, including Sp1 [73] on 
enhancers from myoglobin (an oxidative fibre gene) and MCK (which is preferentially expressed in fast 
fibres). Mef2 activity was first suggested to promote the slow oxidative fibre type based on: (i) the finding that 
Mef2a can cooperate with activated calcineurin protein phosphatase to activate enhancer elements that are 
preferentially expressed in slow/oxidative soleus compared to fast EDL muscle; (ii) the ability of slow-pattern 
electrical activity to activate calcineurin/Nfat signaling; and (iii) the preferential expression of an artificial 
enhancer consisting of three Mef2 binding sites in slow soleus muscle [74-76].  Although the levels of Mef2 
protein appear similar in slow and fast muscles [72], muscle-specific deletion of either Mef2c or Mef2d, but 
not Mef2a, reduced the proportion of slow fibres, whereas over-expression of a Mef2c-VP16 fusion 
increased slow fibre content [72].  The persistence of significant numbers of each fibre type indicates, 
however, that either several Mef2 proteins cooperate or that other regulators of fibre type exist; generation of 
muscle fibres lacking several Mef2s would be of interest. 
Muscle fibre type is not determined solely by electrical activity.  In chick, cell autonomous intrinsic 
differences between early myoblast clones have been suggested to establish fibre type pattern, which is then 
confirmed and refined by innervating motorneurons [77, 78].  Tests have failed to find support for the 
hypotheses that increase in Mef2a or Nfatc activity can drive slow myosin expression in fast myoblasts or 
that Mef2 binding sites operate preferentially in myotubes derived from clones that express slow myosin 
[79].  Moreover, in zebrafish, in which slow and fast fibres are generated before motor innervation, levels of 
Mef2 protein appear similar [29]. Thus, evidence is lacking of an early role of Mef2 leading to persistent 
change in fibre character. 
 
4.  Mechanism of Mef2 action: Transcriptional targets and networks 
 
Having reviewed the known function of Mef2 genes in a range of aspects of muscle differentiation, 
we will now consider the mechanisms of Mef2 action that underpin Mef2 function: how do Mef2s do what 
they do?  To understand the place of a transcription factor such as Mef2 in a cell differentiation program, in 
this Section we consider gene expression.  How is Mef2 expression regulated and what are the Mef2 target 
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genes, the products of which are the effector and realisator molecules that link the transcription factor with 
the cellular (and ultimately the animal) phenotype (see Fig. 2)?  In Section 5, we will consider the Mef2 
proteins and how they are modulated to produce specific outputs. 
 
4.1 Mef2 target genes in the context of development 
 
Analysis of Mef2 target genes indicates the role of Mef2 in the coordination of the gene expression 
programs that underpin muscle differentiation. Much initial progress in understanding the control of muscle 
gene expression came from single gene analysis in cultured muscle cell lines. This type of approach showed 
CRMs of most of the limited number of known muscle genes contained binding sites for Mef2 that are 
functional in cultured cells [7].  However, here we will focus on the physiological differentiation program that 
occurs during animal development. Initial investigations in Drosophila development again using the single 
gene approach, showed that ectopic expression of Mef2 in the ectodermal derivatives induces the ectopic 
expression of a range of muscle genes, including myosin, tropomyosin, ß3-tubulin, nautilus, PS2, muscle-
blind, and muscle LIM [80-83].  In vivo analysis of Mef2 sites in CRMs and in vitro DNA-binding assays 
argued that a number of these genes are direct targets of Mef2, that is Mef2 binds to CRMs of the muscle 
gene to influence its expression [84-88].  However, the relative significance of individual targets to overall 
Mef2 function remained unclear. 
Understanding was transformed by the application of genomic approaches, particularly Chromatin 
Immuno-Precipitation (ChIP) to map where Mef2 binds to genomic DNA.  ChIP identified a significant 
number of potential Mef2 gene targets in both the mammalian C2C12 muscle cell line [43, 89] and in 
Drosophila embryos [90], the latter in conjunction with computational genome scanning for Mef2 sites.  A 
pioneering study then used genomic ChIP in combination with gene expression profiling in Mef2 mutant 
Drosophila embryos to identify Mef2 target genes throughout normal development [91].  A series of time-
points that spanned the period of muscle development was assayed. From this analysis we highlight three 
significant areas: 
 
4.1.1 Number of Mef2 target genes   
Approximately two hundred direct target genes were identified on the basis of having Mef2 binding in 
the vicinity of the transcription unit and expression being affected by Mef2 [91].  This is many more than had 
been anticipated from the pre-genomic era.  Some of these Mef2-binding regions were shown to function as 
muscle CRMs. The total number of Mef2 targets could actually be double that described, because only half 
the genome was covered by the tiling arrays used for the ChIP, and could correspond to most muscle-
specific genes. 
   
4.1.2 Types of Mef2 target genes   
The identified Mef2 target genes were expressed at different times during the differentiation program 
and have diverse functions [90, 91].  Many have roles in different aspects of terminal muscle differentiation, 
including muscle structure, adhesion, fusion, and neuromuscular junction assembly, which supported the 
widely held view of Mef2 as a regulator of the later steps of muscle differentiation [90, 91].  However, there 
had been prior indications of an effect of Mef2 on muscle gene expression earlier than this [86, 92], and a 
striking finding from the genomic approach was that many target genes are expressed early. These genes 
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have roles in the specification and diversification of muscle progenitor cells.  The number and diversity of 
Mef2 target genes expanded the view of Mef2, suggesting a broad role for Mef2 in orchestrating successive 
steps in the muscle differentiation program in vivo during development. 
 
4.1.3 Mef2 target gene specificity   
The list of Mef2 target genes identified in Drosophila suggests that the activity of Mef2 is regulated in 
both space and time.  Mef2 is expressed in the entire myogenic lineage from gastrulation to the end of 
embryogenesis and yet some target genes are expressed early, others late, and yet others in subsets of 
muscle cells [91].  How does this occur? 
One property of Mef2 that is regulated is its binding to chromatin.  There are three temporal profiles 
of CRM occupancy: continuously bound by Mef2; bound early but not late; and bound late but not early [91].  
Moreover, binding of Mef2 to a gene’s CRM is correlated with the onset of that gene’s expression, with the 
correlation particularly strong for the late-bound CRMs [91].  Dynamic Mef2 binding was also found during 
C2C12 differentiation [89]. It is not known what underpins these observations.  One explanation is co-
operative chromatin binding with a differentially expressed factor. Sandmann et al [91] suggest co-operative 
binding with the transiently expressed bHLH protein Twist as a possible explanation for transient Mef2 
binding to the early group of CRMs [91].  Other possible, non-exclusive, explanations include structural 
changes to chromatin, as suggested for the p38 MAPK pathway in a cell culture model of muscle 
differentiation [42], and on modifications of Mef2 (see 5.2). 
Further indications that Mef2 is not an all-or-none regulator came from another genomic approach 
using expression profiling of an allelic series of Mef2 mutant embryos [93]. This revealed that target genes 
expressed early in muscle development require lower levels of Mef2 activity than those expressed later.  The 
idea that levels of Mef2 activity control differential expression of muscle genes had also been suggested 
from expression of different levels of a Mef2 construct in a Mef2-null background [82]. This showed that 
distinct levels of Mef2 are required in Drosophila for particular properties of a muscle cell. 
 
4.2 Vertebrate genomic studies and the emerging gene expression network 
 
Equivalent genomic studies in vertebrate embryonic development to those in Drosophila are 
challenging and have not yet been undertaken.  However, genomic approaches have been applied to good 
effect in cultured cells.  Mef2-regulated genes have been identified in satellite cell-derived myoblasts using 
microarrays for expression profiling [69]. Microarray analysis of genes regulated by Mef2a, Mef2b, Mef2c 
and Mef2d in the C2C12 muscle cell line yielded the significant finding that individual Mef2 family members 
regulate specific subsets of the entire cohort of Mef2-regulated genes [94]. This was not anticipated because 
of the longstanding idea of functional redundancy in the vertebrate Mef2 family, which arose from the 
overlapping patterns of expression and lack of strong single mutant skeletal muscle phenotypes.  ChIP has 
also been used to identify potential Mef2 target genes. In C2 muscle cells, ChIP-seq identified genes bound 
by Mef2d [95], whereas ChIP-exo revealed both common and distinct Mef2a genomic targets in skeletal and 
cardiac muscle cells [96]. These studies, although presenting an incomplete picture, make it apparent that 
understanding how each Mef2 regulates all its targets in a co-ordinated manner is central to understanding 
the network of gene expression that controls the differentiation program of each muscle cell.  
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4.3 Downstream of Mef2: feedback and feed forward 
 
To reveal the organisation of the gene regulatory network, understanding of Mef2 target genes that 
themselves act as regulators is essential.  These include: (1) other transcription factors; (2) microRNAs (Mok 
et al, this special issue); and (3) modulators of Mef2 activity. Here, we highlight some illustrative examples 
(Fig. 2). 
Mef2 targets that encode transcription factors with roles in muscle development have been identified 
in Drosophila embryogenesis [91] and in C2C12 cell differentiation [43].  Each of these transcription factors 
will have its own cohort of target genes.  These may include Mef2 itself (see 4.4), or targets that function with 
Mef2 in part of a feed-forward mechanism [91].  The latter echoes a feed-forward mechanism from MyoD via 
Mef2 and the p38 MAPK in mammalian cultured myoblasts that produces a delay in MyoD target gene 
expression [42].  The intrinsic delay of such feed-forward processes can be part of timing mechanisms 
controlling sequential gene activation in a differentiation program (see 4.4).   
MicroRNAs, which also modulate gene expression, are among the direct transcriptional targets of 
Mef2. Examples include miR-1 and miR-133, and the largest known mammalian microRNA cluster, the Gtl2-
Dio3 locus [49, 97, 98].  The latter is implicated in muscle regeneration.  A documented example of a 
microRNA target that feeds back negatively on Mef2 is miR-92b, which can interact with the 3’UTR of Mef2 
to fine-tune its expression [87]. 
Lastly, other Mef2 targets feed back on Mef2 to modulate its activity. These include HDAC9, a class 
II HDAC, which can associate with Mef2 proteins and suppress their transcriptional activity [99], and 
Drosophila Him, another inhibitor of Mef2 activity [91](Taylor MV, unpublished). How such negative feedback 
loops operate to achieve progress and stasis in the muscle lineage in vivo remains to be determined. 
 
4.4 Closing the Loop: Regulation of Mef2 expression 
 
In vertebrates, MRFs can induce Mef2 mRNA, protein and DNA-binding activity [5, 9, 42, 100].  The 
specific DNA sequence in the mouse Mef2c gene required for its direct activation in vivo by MRFs has been 
defined [101, 102], as have other CRMs for other regulatory inputs [103].  There is also auto-activation of 
Mef2 expression, and this may be direct or indirect. One indirect route is through Mef2 proteins activating the 
expression of MRF genes, which in turn activate Mef2 genes.  Such positive feedback has been described 
for myogenin in both cell culture and developing mouse embryos, and for Myod in satellite cells [104-107].  A 
direct route to auto-activation has been suggested for mouse Mef2c [101], but others have not found this 
[102].   
There are significant parallels in the transcriptional regulation of the Drosophila Mef2 gene. It also 
has multiple CRMs, which indicates the capacity to integrate many regulatory inputs [108].  Notable amongst 
these is the bHLH transcription factor Twist, which activates Mef2 expression [50, 109].  Twist has a major 
role in propelling cells down the myogenic pathway in Drosophila embryogenesis, and its role recalls that of 
the MRF family of bHLH proteins in vertebrates [110, 111].  Mef2 also acts on its own CRM, it auto-activates 
[112]. Other defined inputs include Tinman, which is related to the Nkx2 group of vertebrate transcription 
factors, and the steroid hormone ecdysone that functions in the coordination of metamorphosis [113, 114].  
The cross-activation between Mef2 and the myogenic bHLH factors coupled with the observed auto-
activation, in both Drosophila and vertebrates, points to evolutionarily conserved positive feedback gene 
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transcription loops as a mechanism for cell commitment. These loops can amplify and maintain the 
expression of these key transcription factors with the potential to maintain muscle differentiation.  This is a 
central feature to incorporate into models of the regulatory transcriptional network that underpins muscle 
differentiation (Fig. 2).  
 
4.5 Network features 
 
Taken together, the above information indicates how the network will include both feed-forward and 
feed-back loops and how the activity of nodes like Mef2 in the muscle network might operate. Another aspect 
to incorporate into any model, as emphasised by Cunha et al [115], is the combinatorial and temporal 
features of the regulation of a gene at any node in the network.  Initial steps to assemble this type of 
information have been taken. For example, Twist co-occupies 42% of all Mef2 bound CRMs in the early 
steps of Drosophila mesoderm development [116], and Lmd, a Gli-family transcription factor, modulates 
Mef2 transcriptional output when co-occupying CRMs [115].  
In vertebrates, distinct properties of the different Mef2 and MRF family members also need to be 
considered.  For example, there are aspects of the transcriptional inter-relationship between MRFs and 
Mef2s that are specific to particular members of the two families of transcription factors [117].  More 
generally, there are non-overlapping gene sets in the population of genes regulated by each of the four 
different mouse Mef2 genes, and only a small percentage of genes are co-regulated by all four [94].  Lastly, 
for any specific family member, relationships may not be the same in all situations.  For example, Twist and 
Mef2 are not co-expressed at all stages of Drosophila muscle development.  Clearly, although we can 
highlight key aspects of the network in muscle, much is not understood currently.  Nevertheless, the prize for 
this substantial task of defining the myogenic network will be insights into how robustness of the transcription 
program is achieved and how its activity can respond to different conditions. 
 
5.  Mechanism of Mef2 action: post-transcriptional events 
 
Multiple findings indicate that to comprehend the roles of Mef2 one must understand how its activity 
is regulated. Thus, Mef2 muscle target genes are expressed in both a spatially and temporally regulated 
manner during development (see 4.1). For example, Mef2 protein is expressed in Drosophila muscle 
progenitor cells very many hours before differentiation is underway and many target genes are expressed 
[118]. Although outside the scope of this review, Mef2 also functions in different cell-types to produce distinct 
outputs [21]. Combining these two characteristics, Mef2 may fulfil different functions in time and space within 
the developing and mature skeletal muscle system. Insight into how Mef2 is able to undertake its range of 
roles will require understanding of its post-transcriptional regulation.  Here we highlight alternative splicing, 
protein modifications and protein interactions. Each was identified in the early years of Mef2 research, but 
much has been discovered since. 
 
5.1 Alternative splicing  
 
One way to diversify gene function is through alternative RNA splicing.  Mef2 proteins across the 
metazoa show many small conserved regions throughout their length, in addition to the highly conserved N-
Taylor and Hughes Mef2 Pg  13 
terminal MADS/Mef2 domain (Fig. 1).  Furthermore, evolution has varied Mef2 gene products through 
alternative splicing, which appears to focus in specific regions, presumably those most forgiving of alteration, 
yet controlling function.  For example, although Drosophila Mef2 shows little conservation beyond the 
conserved N-terminal regions, the locations of exon borders and alternative splice sites are similar to those 
in vertebrate Mef2 genes. Two splice variants map to the region of the vertebrate alternatively spliced  exon, 
despite lacking obvious sequence homology (designated exon 8 and ’ in Fig. 1) [50, 82]. In vertebrates, 
specific alternative splice variants in these regions are generated in muscle, but Drosophila Mef2 isoforms 
have yet to reveal distinct function [82].  Even diploblasts, e.g. jellyfish and sea anemone, appear to require 
full length Mef2 for their mesendoderm-derived myogenesis and show good conservation to vertebrate 
Mef2s, with regions of alternative splicing matching a subset of those in vertebrates [119, 120]. Despite this 
conservation, individual species have sometimes lost domains. Downstream of the N-terminus C. 
elegans Mef2 lacks most homologous regions, except for a C-terminal stretch matching the -exon, but it is 
not essential in myogenesis [121].  Such changes suggest that specific Mef2 sub-functions may only be 
retained in Mef2 genes of some species. 
The multiplication of vertebrate Mef2 genes has permitted gene diversification.  Mef2b genes show 
significantly greater divergence and lack two exons, obvious muscle-specific splice variants and several 
conserved domains [122].  In contrast, Mef2a, -c and -d genes have generally maintained alternative 
splicing, suggesting that each retains distinct functions in their splice variants (Fig. 1).  Specific functions 
have been addressed in cell culture studies.  Muscle-specific splicing of exon 3 occurs in Mef2a, -c and -d [9, 
123-126]. In Mef2d, this seems to regulate responsiveness to PKA signaling that can control myoblast 
differentiation, whereas in Mef2c it controls responsiveness to kinases regulating the cell cycle and growth 
[95, 123, 127].  Splicing at other locations may modulate the efficacy of Mef2 in myogenesis by controlling its 
interaction with MyoD, responsiveness to signals and transcriptional activity [36, 128, 129].    
Of potential clinical relevance, inclusion of exon 32 in Mef2c is diminished in rhabdomyosarcoma 
cells and replacement can reverse transformation and promote their terminal differentiation [130]. Moreover, 
altered Mef2 splicing may contribute to myotonic dystrophy [131].  Mechanistic understanding of Mef2 
alternative splicing is rudimentary, and whether similar splice variants show common functional differences in 
various tissues or between genes remains unclear [67, 132].  Further studies are therefore essential to 
understand the regulation of alternative splicing and the functional roles of each isoform produced in muscle 
tissue in vivo. 
 
5.2  Mef2 modification 
 
Since the demonstration that phosphorylation of the MADS/Mef2 domain Mef2 in cultured cells could 
increase its DNA-binding activity [133], many different types of modification in different domains of Mef2 
have been reported.  These include the following illustrative examples in cultured muscle cell lines.  p38 
MAPK phosphorylates Mef2 at a number of sites and Thr293 phosphorylation of Mef2c is linked to enhanced 
transcriptional activity [134]. p38 also regulates the formation of DNA-binding Mef2/MyoD complexes and 
RNA PolII recruitment [42]. Mef2d is phosphorylated by PKA at Ser121 and Ser190 and this is linked to 
repressed transcriptional activity [135]. Transcriptional activity of Mef2D is also repressed by methylation at 
Lys267 [136] and by sumoylation at Lys439 in the C-terminal activation domain [137].  Another modification 
linked to Mef2 function is acetylation.  In Mef2c this occurs at Lys4 [138] and at multiple sites in the activation 
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domain [139]. In both cases, modification is differentiation-dependent and DNA-binding activity is enhanced. 
In general, much remains unknown concerning the effects of these modifications and their significance in 
vivo during muscle development. Nevertheless, one example with intriguing in vivo findings is p38 MAPK, 
which is required for Mef2 activity and for muscle differentiation in mouse development [140].  In Drosophila, 
p38 activity in muscles regulates motor function and was shown to work through Mef2 in the regulation of life 
span [141]. This brief survey indicates that Mef2 proteins can be covalently modified in a variety of ways and 
that these modifications are a route to modulating Mef2 protein function. 
 
5.3 Mef2 protein interactions 
 
Shortly after its discovery it was apparent that protein interactions were significant to Mef2 function: it 
both dimerised and interacted with the MRFs [8, 41, 142].  Protein interactions can produce specific 
outcomes, and one largely unexplored aspect is whether the potentially large number of different Mef2 
dimers have different functions. Most Mef2 protein interaction studies have been in vitro or in cell culture, 
and have been recently reviewed [143]. Here we highlight some examples with significance to Mef2 function 
in muscle. 
Mef2 proteins interact with other transcription factors in addition to the MRFs.  These include Smad 
proteins, which can bind to Mef2 in muscle cells and functionally co-operate in transcription assays [144]. 
The latter is dependent on p38 phosphorylation sites (see 5.2).  Klf5 is a zinc finger transcription factor 
required for muscle regeneration in vivo and muscle differentiation in cell culture [145].  Klf5 directly 
associates with MyoD and Mef2 in vitro, and ChIP shows overlap with its chromatin sites and those bound by 
Mef2 and MyoD. The transcriptional adapter nTRIP6 can bind to Mef2c and repress target gene expression 
in myoblasts [146]. Intriguingly, TRIP6 can interact with Nup210 in a nuclear pore complex implicated in 
muscle gene expression control [147]. In the context of temporal control, the Nfix transcription factor that 
regulates fetal-specific muscle gene transcription binds to and enhances PKC-mediated phosphorylation of 
Mef2a and target gene expression [148]. In Drosophila, Mef2 can bind the myogenic bHLH protein Twist 
[149], paralleling the vertebrate MRF finding, and Twist co-occupies 42% of all Mef2-bound CRMs [116]. 
Mef2 can also bind two other transcriptional regulators with roles in muscle development, Sd and Vg, related 
to vertebrate TEAD and Vgl-2 respectively [149, 150].   
Notable amongst the Mef2-interacting proteins are the class IIa HDACs.  They can interact with Mef2 
proteins and inhibit their activity, and over-expression can inhibit differentiation of muscle cell lines, a 
function linked to cytoplasmic/nuclear shuttling [151-153]. In vivo, class IIa HDACs suppress the formation of 
slow muscle fibres through repression of Mef2 activity [72].  Conversely, the acetyltransferase p300 can bind 
to Mef2c and thereby augment its transcriptional activity [154]. Lastly, the proline isomerase Pin1, which 
inhibits muscle differentiation in culture, can bind Mef2c isoforms containing the 31 exon upon 
phosphorylation of two Ser-Pro sites [155]. Over-expression of Pin1 decreases Mef2c stability and activity, 
likely through an induced conformational change. 
 The above examples illustrate how some Mef2 interactions with other transcriptional regulators 
might operate in the context of CRMs that contain cognate binding sites for each transcription factor. Others, 
for example Vg/Vgl-2, which has no DNA-binding domain, might require just one site, or be independent of 
DNA-binding.  They also illustrate how protein modification and protein interaction are closely inter-related. In 
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order to trigger modification there must be at least a transient interaction, and some interactions may be 
dependent on prior protein modifications. 
 
6. Coda: Conclusions and future directions  
 
The family of Mef2 genes is well-characterised and a lot is known about the roles of the encoded 
Mef2 transcription factors in muscle cells.  However, there are significant gaps to fill in linking findings in cell 
culture to the in vivo muscle differentiation program. First, what do the different Mef2 genes do?  Second, 
Mef2 genes produce different proteins by alternative splicing, and these proteins can undergo post-
translational modifications and interact with diverse partner proteins. Understanding how these features 
impact on Mef2 protein activity to produce specific transcriptional outputs will be pivotal to a full 
understanding of Mef2 function within the muscle differentiation program. Moreover, although we have 
focussed on Mef2 in skeletal muscle, Mef2 has roles in other cell-types [14, 21, 156-158], and therefore, 
similar analyses in different tissues may illuminate Mef2 roles in muscle. 
An unknown is the ancestral function of Mef2.  As mentioned above, in some species, Mef2 is 
neither expressed in muscle, nor required for myogenesis [121, 159].  In these species it is possible that 
another MADS protein, an SRF family homologue, fulfils a Mef2-like role [160]. SRF and Mef2 homologues 
exist in yeast and regulate cell shape and stress-resistance [161].  As, in animals, SRF is a fundamental 
actin sensor [162] and muscle evolved as an extreme adaptation of the actomyosin cytoskeleton [163], 
modification of an actin-sensor system involving a MADS protein may have participated in the evolution of 
muscle.  Such thinking indicates that in considering the various extant functions of Mef2 proteins, it will be 
helpful to identify conserved ancestral Mef2 function(s) and the evolutionary clades in which specific new 
roles evolved.  
 A core area for future work is the transcription network that underpins the muscle phenotype. The 
first steps to understand this on a genomic scale during development have been taken in Drosophila.  
Linking in vivo functional networks to the regulatory layers of chromatin and nuclear organisation will be 
illuminating.  For example, p38 signalling to Mef2D can recruit a chromatin modifier to muscle gene CRMs 
[164, 165], and spatial organisation of the CRMs of muscle genes is reported to contribute to temporal 
regulation of expression [166]. In a similar vein, a Mef2c-containing complex has been described assembled 
at the nuclear pore to regulate muscle gene expression, development and maintenance [147].  Integration of 
these additional regulatory layers with more conventional gene expression studies will produce an in-depth 
understanding of the muscle differentiation program. 
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Figure legends 
 
Figure 1 Alignment of Mef2 Structure and Functions.   
Top row: named protein domains and their sizes. HJURP-C Holliday Junction Recognition  
Protein C-terminal Domain, TAD Transactivation domain, NLS nuclear localisation sequence.   
Second row: Conserved vertebrate exon structure (approximately to scale) showing alternative splices with 
nomenclature following Ganassi et al (2014). Vertical black lines denote exon boundaries.  Grey boxes 
indicate alternate splice donor/acceptor sites.  
Third row: conservation of domains is indicated by colour intensity (lengths not to scale). Species showing 
conserved regions are listed beneath: Hs Homo sapiens, Dr Fish Danio rerio, Brachi Brachiopod Terebratalia 
transversa, Ce Nematode Caenorhabditis elegans, Dm Fly Drosophila melanogaster, Pc Jellyfish 
Podocoryne carnea, Nv Sea anemone Nematostella vectensis.   
Fourth to sixth rows: conserved exon structure and splice locations in Dm and Nv and lesser central 
conservation in Ce.  Exon length differences are indicative, but not to scale. 
 
 
Figure 2.   Schematic model of Mef2 at a nexus in the network of gene expression that underpins the 
muscle differentiation program 
1.  Mef2 transcription is stimulated by the muscle bHLH proteins and by direct and indirect auto-regulatory 
loops (in red) and other inputs. 
2.  Mef2 transcripts are alternatively spliced. 
3.  Distinct Mef2 proteins are produced from different RNAs and different paralogous genes. They form 
dimers with the potential for distinct functions 
4. Mef2 proteins activate a series of targets (arrows indicate the possibility of shared and distinct targets 
between different Mef2 proteins).  The effectors include other transcription factors, microRNAs and other 
regulators (e.g. HDACs), which can feedback onto Mef2 though different routes (in blue). Mef2 plus these 
transcription factors can feed-forward (7) onto realisator genes (6). 
5. The activity of Mef2 protein is modulated by modifications (X and Y), interaction with other proteins, 
including transcription factors and other regulators e.g. HDACs. 
6. Mef2 proteins in different contexts/forms activate a range of realisator genes over space and time to 
produce the muscle phenotype. 
7.  Some realisator genes may be activated by a feed-forward mechanism. 
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